The FDA updated Genentech’s Xeloda (capecitabine) label to explicitly recommend pre‑treatment testing for DPYD variants that confer dihydropyrimidine dehydrogenase (DPD) deficiency, elevating genetic screening from "consider" to a boxed warning when feasible. The move follows patient-advocate pressure and workshops with oncology stakeholders and aligns labeling with guideline updates from major cancer societies. In parallel, the Association for Molecular Pathology released standardized biomarker-reporting recommendations to help labs convey complex NGS results to clinicians. AMP’s template aims to improve clarity around variant interpretation and actionable recommendations — a practical complement to the FDA’s push for genotype‑guided chemotherapy safety. Clarification: DPYD testing identifies patients at genetic risk for severe fluoropyrimidine toxicity so dosing can be adjusted or drugs avoided.